AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of ... MarketWatch (press release) ... R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus - both of which have commenced Phase II clinical trials; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune ... |
